Anthropometric and metabolic parameters in 46 hypogonadal men with obesity grade III improve upon long-term treatment with testosterone undecanoate (TU) injections: Observational data from two registry studies

Farid Saad; Ahmad Haider; Aksam Yassin; Gheorghe Doros; Abdulmaged Traish

doi:10.1530/endoabs.35.P755

P755

Prev Next

Section Contents Cite

Endocrine Abstracts (2014) 35 P755 | DOI: 10.1530/endoabs.35.P755

ECE2014 Poster Presentations Obesity (53 abstracts)

Anthropometric and metabolic parameters in 46 hypogonadal men with obesity grade III improve upon long-term treatment with testosterone undecanoate (TU) injections: Observational data from two registry studies

Farid Saad ^1, , Ahmad Haider ³ , Aksam Yassin ^4, , Gheorghe Doros ⁶ & Abdulmaged Traish ⁷

Author affiliations View ePoster Download ePoster

¹Global Medical Affairs Men’s Healthcare, Bayer Pharma, Berlin, Germany; ²Gulf Medical University School of Medicine, Ajman, United Arab Emirates; ³Private Urology Practice, Bremerhaven, Germany; ⁴Institute of Urology and Andrology, Norderstedt, Germany; ⁵Dresden International University, Dresden, Germany; ⁶Department of Epidemiology and Statistics, Boston University School of Public Health, Boston, Massachusetts, US; ⁷Department of Biochemistry and Department of Urology, Boston University School of Medicine, Boston, Massachusetts, USA.

Introduction: Numerous studies have reported inverse associations between testosterone and obesity as well as other components of the metabolic syndrome.

Methods: From two registry studies of 561 hypogonadal mens, 46 mens with obesity grade III (BMI ≧40 kg/m²) were selected. All patients received TU injections for up to 6 years. 46 mens were followed for 2 years, 43 for 3 years, 37 for 4 years, 34 for 5 years, and 24 for 6 s. Declining numbers are result of the registry design.

Results: Weight (kg) decreased from 129.02±5.67 to 103.33±4.17, mean change from baseline −27.15±0.74 kg, percent change from baseline −20.99±3.16%. Waist circumference (cm) decreased from 118.41±5.69 to 106.48±4.91, mean change from baseline 12.44±0.36 cm. BMI (kg/m²) decreased from 41.93±1.5 to 33.62±1.58, mean change from baseline −8.79±0.23 kg/m².

Mean fasting glucose (mg/dl) decreased from 115.48±23.85 to 96.54±2.9 (P<0.0001), mean change from baseline −18.48±2.96 mg/dl, HbA_1c (%) from 7.57±1.38 to 6.08±0.5, mean change from baseline −1.61±0.13%.

Total cholesterol (TC; mg/dl) decreased from 306.76±43.03 to 192.23±9.17 (<0.0001), LDL (mg/dl) from 190.57±36.6 to 136.24±28.07 (P<0.0001), triglycerides (mg/dl) from 326.87±60.21 to 194.4±12.59 (P<0.0001). HDL (mg/dl) increased from 62.76±18.7 to 72.55±13.34 (P<0.0001). The TC:HDL ratio declined from 5.47±2.57 to 2.75±0.59 (P<0.0001). Systolic blood pressure (mmHg) decreased from 161.04±14.3 to 142.05±9.57, diastolic blood pressure from 97.07±10.91 to 80.89±6.76.

Liver enzymes AST and ALT (U/L) decreased from 42.39±17.84 to 20.33±1.9 and from 43.52±20.68 to 20.43±2.75 respectively (P<0.0001 for both), suggesting a reduction in liver fat content.

C-reactive protein (CRP, mg/l) declined from 3.96±4.31 to 0.57±0.59 (P<0.0001).

There were no drop-outs.

Conclusions: All changes were in a clinically meaningful magnitude and sustainable for the full observation period. TRT seems to be an effective approach to achieve sustained weight loss in excessively obese hypogonadal men.